A recent study indicates that individuals who stop using blockbuster slimming jabs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who end conventional lifestyle programs.
Published data in a leading health publication demonstrates that while obese individuals can lose substantial amounts of their body weight while on the medication, the weight is regained at an estimated rate of nearly a kilo each month after stopping.
"People purchasing these medications need to be cognizant of the potential of fast rebound weight gain when the therapy ends," warns expert Dr. Susan Jebb.
That rate of recovery suggests a reversion to original weight in about 18 months.
Analyzing Approaches
The study, which reviewed 37 of trials involving thousands of patients, compared the results of these new drugs with older methods.
Researchers point out that individuals who lose weight through lifestyle changes alone generally see a slower weight regain—approximately 0.1 kg a month—once they finish.
Explaining the Fast Regain
Nutrition scientists propose the way of the drugs explains the accelerated weight return.
These medications mimic a natural hormone called GLP-1, which controls hunger.
"Long-term administration of GLP-1 concentrations far above than normal might result in the system to produce less of its endogenous GLP-1, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a nutrition expert.
"Withdrawal of this GLP-1 'fix' means appetite is uncontrolled, making overeating a significant risk."
A Lifelong Disease?
The NHS suggest the injections for individuals with obesity-related health risks, alongside recommended diet and exercise modifications.
Professionals say that, due to the likelihood of weight regain, the therapy should be considered long-term.
This perspective is echoed by pharmaceutical companies, who note that the results "emphasize the chronic character of excess weight," comparing it to managing diseases like diabetes.
Patient Accounts
Users who have stopped the jabs explain a intense return of cravings.
"I experienced something flipping and I was suddenly starving," described a patient.
The struggle is compounded if users have not developed permanent dietary or behavioural modifications during therapy.
Significant Use
Recent estimates indicate that millions of adults in the UK have used these injections in the past year, with interest being substantial.
- Adoption is greater among women than males.
- The 40s and 50s age group shows the highest usage rates.
- Many obtain the medications through private healthcare rather than public health services.
Ultimately, experts caution that while these medications are potent tools for weight loss, they are not a permanent fix and maintained weight loss relies on integrated behavioural changes.
